Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Nano-crystalline Megestrol Acetate for Adjuvant Treatment in High-risk Head and Neck Squamous Cell Carcinoma After Surgery. (NCT06772428) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2025-01-01 |
Track Head and Neck Squamous Cell Carcinoma; Underwent Surgery Within 6 Weeks and Postoperative Assessment Indicated High-risk Factors automatically
Every clearance here is in the API, with alerts when new ones post.